Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies

BACKGROUND: The current study aims to fabricate Nanostructured Lipid Carriers for the co-delivery of Alectinib and Hesperidin (ALB-HSD NLC) for non-small cell lung Cancer (NSCLC) via an inhalational route. RESEARCH DESIGN AND METHOD: studies. RESULTS: studies give significant results on the syngeneic model. CONCLUSIONS: The prepared ALB-HSD NLC could be promising drug carriers, and they succeeded in delivering small and efficient doses of ALB and HSD to treat NSCLC.